Substantia Nigra Neurons In Progressive Supranuclear Palsy is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
Progressive supranuclear palsy (PSP) is a tauopathy characterized by vertical gaze palsy, postural instability, and parkinsonism. The substantia nigra (SN) shows significant neurodegeneration, contributing to the motor symptoms that resemble Parkinson's disease but with distinct pathological features.
- SNc Pigmented Neurons: Marked loss (60-80%)
- SNr Neurons: Less affected than SNc
- Pattern: Dorsomedial SNc most vulnerable
- Correlation: Severity with disease duration
- Neurofibrillary Tangles: Abundant NFTs in surviving neurons
- Tau Thread Pathology: Thread-like processes
- 4R Tau Predominance: Isoform specificity
- Globose NFTs: Characteristic NFT shape
- Striatal Dopamine: Severe depletion
- Pattern: More uniform than PD
- Putamen > Caudate: Gradient of loss
- Tyrosine Hydroxylase: Markedly reduced
- Dopamine: 70-90% depletion
- DAT Binding: Severely reduced on imaging
- Hyperphosphorylation Sites: Ser202, Thr231, Ser396
- Oligomerization: Toxic tau oligomers
- Prion-like Spreading: Template-directed propagation
- Oxidative Damage: 4-HNE accumulation
- Mitochondrial Dysfunction: Complex I inhibition
- Endoplasmic Reticulum Stress: UPR activation
- Bradykinesia: Central feature
- Rigidity: Axial > limb
- Postural Instability: Early falls characteristic
- Vertical Supranuclear Gaze Palsy: Downgaze first
- Slow Saccades: Predictive of PSP
- Blepharospasm: Common
- Pseudobulbar Palsy: Dysarthria, dysphagia
- Frontal Signs: Executive dysfunction
- Cognitive Impairment: Subcortical pattern
| Feature |
PSP |
PD |
| Gaze palsy |
Present |
Absent |
| Falls |
Early |
Late |
| Tremor |
Rare |
Common |
| Symmetry |
Bilateral |
Unilateral initially |
| Levodopa response |
Poor |
Good |
| Feature |
PSP |
CBD |
| Gaze palsy |
Prominent |
Rare |
| Apraxia |
Rare |
Common |
| Axial rigidity |
Marked |
Variable |
| Cortical signs |
Late |
Early |
- Levodopa: Minimal to moderate benefit
- Botulinum Toxin: For dystonia
- Speech Therapy: For dysarthria
- Tau-directed immunotherapies
- Antisense oligonucleotides
- Neuroprotective agents
The study of Substantia Nigra Neurons In Progressive Supranuclear Palsy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Williams DR, et al. Neuropathology of progressive supranuclear palsy. Brain. 2005;128(Pt 6):1250-1258. PMID:15858568
- Hauw JJ, et al. Clinicopathological classification of progressive supranuclear palsy. Neurology. 1994;44(11):2033-2039. PMID:7969957
- Dickson DW, et al. Neuropathology of progressive supranuclear palsy. J Neural Transm. 2014;121(12):1435-1441. PMID:24825566
- Litvan I, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy. Neurology. 1996;46(4):922-930. PMID:8780075
- Respondek G, et al. Neuropathologic diagnosis of progressive supranuclear palsy: current status and future directions. Mov Disord. 2015;30(10):1317-1328. PMID:26293498
- Armstrong MJ, et al. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 2019;18(3):271-282. PMID:30821943
- Ahmed Z, et al. Tau pathology in progressive supranuclear palsy: ultrastructural studies and pathological correlations. J Neural Transm. 2012;119(6):723-733. PMID:22290474
- Jellinger KA. Neurobiology of progressive supranuclear palsy. Neurol Sci. 2001;22(3):247-259. PMID:11816151